Navigation Links
Covance Opens New Clinical Development Offices in Brazil and Mexico
Date:9/9/2009

PRINCETON, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced the opening of new clinical development offices in Sao Paolo, Brazil and Mexico City, Mexico. These offices further expand Covance's global footprint with a comprehensive range of services across Latin America. Earlier this year, Covance announced new offices in Santiago, Chile and Lima, Peru. These new sites will support staff in these countries, Central America, and the Caribbean, as well as the regional network of field-based clinical research associates in the region.

Covance has been providing clinical trial support in Latin America since 1997 with the company's first office in Buenos Aires, Argentina. Operations in the region expanded quickly through a network of regional clinical trial monitors trained and supervised under guidelines meeting both local and international regulatory requirements as well as global Covance quality standards.

"Our continued expansion in Latin America highlights the region's growing significance in Covance's clinical development service offerings. These new offices increase our access to patients who are currently not receiving medical therapies and will enable us to shorten clinical trial cycle times for our pharmaceutical and biotech clients," said Wayne Langlois, vice president and general manager of global clinical development services at Covance.

"The clinical trials we conduct in Latin America are part of a carefully weighted site selection approach that not only produces high-quality data on time, but also satisfies the requirements of regulatory authorities," said Katie Margules, senior director for Latin America.

Covance offers clinical development services for Phase I to III clinical trials in more than 55 countries which include emerging markets across Asia Pacific, Central and Eastern Europe, and Latin America. With a full suite of services to take a drug through all stages of development, Covance offers extensive clinical and therapeutic expertise, global reach, proactive project management, and strong investigator site relationships to consistently deliver high quality data on time.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the UBS Global Life Sciences Conference
2. Covance Elects Dr. Gary E. Costley to Board of Directors
3. Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRTs Centralized Cardiac Safety Services
4. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
5. eResearchTechnology, Inc. to Announce Agreement to Acquire the Centralized ECG Business of Covance
6. Covance and Care Partner on Rwanda Early Childhood Development Initiative
7. Wendel Barr Appointed Chief Operating Officer of Covance
8. Covance to Present at 26th Annual JPMorgan Healthcare Conference
9. Covance to Present at UBS Global Healthcare Services Conference
10. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
11. Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... ... The weather is heating up and the days are getting longer, providing ... that the summer months provide more than warmer temperatures that are perfect for BBQ’s ... affected from direct exposure to the sun. When it comes to the security of ...
(Date:6/23/2017)... Beach, CA (PRWEB) , ... June 23, 2017 , ... ... has earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, ... in the top 1% of all charities reviewed by Charity Navigator and earns ANRF ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... practicing in Newburgh, New York, has recently begun offering three new minimally invasive ... the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to bring ...
(Date:6/23/2017)... ... , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach ... proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does more ... can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care opened its ... facility overall and marks the urgent care center's eighth location in Miami-Dade county. , ... Falls shopping mall. The new clinic offers a wide array of services ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  StatLab Medical ... developer and manufacturer of diagnostic supplies for ... that Cressey & Company LP ("Cressey & ... completed a growth-focused investment in the Company. ... ownership position from selling shareholder, Prairie Capital, ...
(Date:6/7/2017)... Iowa , June 6, 2017  Diplomat Specialty Infusion Group, ... sterile compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard ... controlled environment with a low level of pollutants. ... more IV nutrition consumers and better serve our Iowa ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: